RECURSION PHARMACEUTICALS, INC. 4

CEO and President Najat Khan had 80,498 shares of Recursion Pharmaceuticals Class A Common Stock withheld for tax on RSU settlement, retaining 2,095,298 shares afterward.

On August 17, 2026, Najat Khan, CEO and President of Recursion Pharmaceuticals, Inc., had 80,498 shares of Class A Common Stock withheld by the company at an implied price of $3.16 per share, totaling approximately $254,373, to cover tax withholding obligations arising from the net settlement of restricted stock units. This Form 4 reflects a routine, non-open-market disposition for tax purposes rather than a discretionary sale, and following the transaction Khan continued to hold 2,095,298 shares of Class A Common Stock.

Filing Facts

CIK

1601830

Ticker

RXRX

Form

4

Source Type

fda

Accession

0002020969-26-000006

Alert Tier

5